You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
奇正藏藥(002287.SZ):2021年度淨利預增89.00%-104.00%
格隆匯 01-27 15:55

格隆匯1月27日丨奇正藏藥(002287.SZ)披露2021年度業績預吿,預計2021年度實現歸屬於上市公司股東的淨利潤7.63億元至8.24億元,同比增長89.00%至104.00%;預計2021年度實現歸屬於上市公司股東的扣除非經常性損益後的淨利潤3.25億元至3.85億元,同比變動-5.24%至12.44%。

公司2021年年度業績較上年同期增加的主要原因為:百洋醫藥(301015.SZ)上市後,公司參與設立的併購基金西藏羣英投資中心(有限合夥)(簡稱“羣英投資”)以公開市場的價格確認公允價值變動損益增加收益,公司對此投資按照權益法確認損益,按照協議約定增加公司2021年年度淨利潤約3.37億元;該事項屬於非經常性損益。同時,由於羣英投資公允價值變動損益受百洋醫藥二級市場股價波動影響較大,間接影響公司投資收益,可能會導致公司業績存在一定的波動。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account